• Wion
  • /India News
  • /Omicron BA-2.75: All you want to know about the new Covid subvariant in Delhi

Omicron BA-2.75: All you want to know about the new Covid subvariant in Delhi

Omicron BA-2.75: All you want to know about the new Covid subvariant in Delhi

Omicron

As India's national capital continues to witness a surge in coronavirus cases, a new subvariant of Omicron has beendetected in New Delhi, identified as BA-2.75.

On Tuesday, Delhi reported 2,495 new COVID-19 cases with the positivity rate touching 15.41 per cent. The capital also recorded seven deaths, according to the health department. The number of virus cases in Delhi is highest since January, reports say. On Saturday, the capital reported 2,423 virus cases with a positivity rate of 14.97 per cent, including two fatalities, and on Wednesday, the capitalreported over 2,000 COVID-19 along with five fatalities.

Also Read:Man claims he had monkeypox and coronavirus at the same time

Add WION as a Preferred Source

What is the new Omicron sub-variant BA-2.75?

According to doctors in Delhi, the BA-2.75 was detected in 90 samples as reports claim it infects people with antibodies and is alsomore transferable. It also infects those who have taken the coronavirus vaccine. The BA.2.75 subvariant is the descendent of Omiron subvariant BA.2 and is reportedly different from BA.5.

Watch:Authorities race to contain COVID-19 surge in China's Hainan

BA.4 and BA.5 subvariants of Omicron are the dominant virus strains worldwide currently. Reports claim the first BA-2.75 case in India was detected in May, with cases reported in 10 states in the country.

Rajeev Jayadevan, co-chairman, National Indian Medical Association Covid Task Force, said that although BA.2.75 has certain mutations that have attracted global attention, "from the limited samples available there are no reports yet of severe disease or excessive spread."

What does the World Health Organization say about BA.2.75?

According to the World Health Organization(WH0), the BA.2.75 subvariant indicated "major immune escape" and has a "clear growth advantage" over other variants in India. The WHO has been monitoring the BA.2.75 sub-variant closely.

WHO's chief scientist Soumya Swaminathan added that it was "it is too early to know that this sub-variant has properties of being more clinically severe".

(With inputs from Agencies)

WATCH WION LIVE HERE

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

About the Author